Girl’s death in China: Does gene editing therapy need better regulation? | In Focus Podcast

The death of a six-year-old girl in China following experimental gene editing therapy has sparked a global debate on medical ethics and regulation. Experts are questioning the oversight of experimental treatments and the risks associated with base editing in clinical settings.
The scientific world was rocked last month, when the case of a six-year-old girl who died in China, surfaced. The child was believed to have Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder caused by a mutation in the CHD3 gene. The condition affects intellectual development, but its severity varies widely. The girl’s parents sought an experimental treatment led by neuroscientist Zilong Qiu at the Shanghai Jiao Tong University.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in